The EVEREST I trial was a prospective, multi-center, registry trial designed to evaluate
the preliminary safety and effectiveness of the MitraClip device in the treatment of
moderate-to-severe (3+) or severe (4+) chronic MR using up to 2 MitraClip devices per
patient. The EVEREST I trial demonstrated the preliminary safety and feasibility of the
MitraClip device as a percutaneous method for the reduction of MR severity. EVEREST
I enrolled 55 patients at 12 US sites. Enrolled patients were required to complete clinical
follow up at 30 days, 6, 18 and 24 months, and 3, 4, and 5 years. The primary safety
endpoint of EVEREST I was MAE rate through 30 days (acute safety). Multiple
additional secondary endpoints were pre-specified for safety and effectiveness for
reporting with descriptive statistics. The study is now closed.